BTC Health (ASX:BTC) secures exclusive rights for Exstent's ExoVasc aortic support device

BTC Cardio, a subsidiary of BTC Health, secured an exclusive distribution rights for Exstent's ExoVasc personalised external aortic root support device.

ExoVasc, designed to manage aortic dilation in genetic conditions like Marfan syndrome, targets substantial sales revenue, forecasted at $700,00 in the first year, with a growth projection of 10%-15% annually.

The device, with over 1000 patients benefiting since its inception in 2004, sets a new standard in aortic management.

BTC Cardio assumes full responsibility for ExoVasc, succeeding Advanced Biomedical in Australia, with a transfer fee of up to $200,000.